PURPOSE: The aim of this study was to evaluate the prognostic value of the WHO proposal, to assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) classified into WHO subgroups, and to estimate mortality (standardized mortality ratio [SMR]) and life expectancy in these groups as a basis for clinical decision making. PATIENTS AND METHODS: Four hundred sixty-seven patients who were diagnosed as having de novo MDS at the Division of Hematology, University of Pavia (Pavia, Italy), between 1992 and 2002, were evaluated retrospectively for clinical and hematologic features at diagnosis, overall survival (OS), and progression to leukemia (leukemia-free survival). RESULTS: Significant differences in survival were noted b...
BACKGROUND AND OBJECTIVE: Despite the fact that several prognostic systems for myelodysplastic syndr...
We evaluated the impact of World Health Organization (WHO) classification and WHO classification-bas...
We evaluated the impact of World Health Organization (WHO) classification and WHO classification-bas...
PURPOSE: The aim of this study was to evaluate the prognostic value of the WHO proposal, to assess t...
Myelodysplastic syndromes (MDS) are a group of hematologic disorders that occur mainly in older pers...
The WHO classification for myelodysplastic syndromes (MDS) has introduced new categories with progno...
A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the W...
PURPOSE: The aims of this study were to identify the most significant prognostic factors in myelodys...
Background: Accurate prediction of a patient’s prognosis is useful to define the risk posed by the d...
Myelodysplastic syndromes (MDS) are acquired clonal disorders of hematopoiesis, that are characteriz...
Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematologic disorders characteriz...
The clinical heterogeneity of myelodysplastic syndromes (MDS) is best illustrated by the observation...
BACKGROUND AND OBJECTIVE: Despite the fact that several prognostic systems for myelodysplastic syndr...
We evaluated the impact of World Health Organization (WHO) classification and WHO classification-bas...
We evaluated the impact of World Health Organization (WHO) classification and WHO classification-bas...
PURPOSE: The aim of this study was to evaluate the prognostic value of the WHO proposal, to assess t...
Myelodysplastic syndromes (MDS) are a group of hematologic disorders that occur mainly in older pers...
The WHO classification for myelodysplastic syndromes (MDS) has introduced new categories with progno...
A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the W...
PURPOSE: The aims of this study were to identify the most significant prognostic factors in myelodys...
Background: Accurate prediction of a patient’s prognosis is useful to define the risk posed by the d...
Myelodysplastic syndromes (MDS) are acquired clonal disorders of hematopoiesis, that are characteriz...
Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematologic disorders characteriz...
The clinical heterogeneity of myelodysplastic syndromes (MDS) is best illustrated by the observation...
BACKGROUND AND OBJECTIVE: Despite the fact that several prognostic systems for myelodysplastic syndr...
We evaluated the impact of World Health Organization (WHO) classification and WHO classification-bas...
We evaluated the impact of World Health Organization (WHO) classification and WHO classification-bas...